

Supplementary Table S2. Descriptive distribution of key MRONJ knowledge and clinical-approach items across the eight individual dental specialties.

Data are presented as n (%) within each specialty. Owing to the small number of participants in each specialty (n = 4–8), only descriptive results are provided; no between-specialty significance tests were conducted. The “All specialists” column shows the pooled specialist results reported in Table 2 of the main text.

Item	Oral and Maxillofacial Radiology (n = 6)	Oral and Maxillofacial Surgery (n = 8)	Endodontics (n = 8)	Prosthodontics (n = 6)	Restorative Dentistry (n = 6)	Periodontology (n = 6)	Pediatric Dentistry (n = 6)	Orthodontics (n = 4)	All specialists (n = 50)
Bone metastases of solid tumours ^a	4 (66.7%)	8 (100.0%)	7 (87.5%)	4 (66.7%)	6 (100.0%)	5 (83.3%)	6 (100.0%)	2 (50.0%)	42 (84.0%)
Multiple myeloma ^a	5 (83.3%)	6 (75.0%)	2 (25.0%)	1 (16.7%)	2 (33.3%)	3 (50.0%)	3 (50.0%)	1 (25.0%)	23 (46.0%)
Alendronate ^b	4 (66.7%)	8 (100.0%)	6 (75.0%)	1 (16.7%)	1 (16.7%)	5 (83.3%)	4 (66.7%)	0 (0.0%)	29 (58.0%)
Pamidronate ^b	4 (66.7%)	7 (87.5%)	3 (37.5%)	3 (50.0%)	3 (50.0%)	4 (66.7%)	4 (66.7%)	1 (25.0%)	29 (58.0%)
Zoledronate ^b	6 (100.0%)	7 (87.5%)	7 (87.5%)	3 (50.0%)	5 (83.3%)	5 (83.3%)	4 (66.7%)	3 (75.0%)	40 (80.0%)
Denosumab ^b	5 (83.3%)	7 (87.5%)	3 (37.5%)	3 (50.0%)	1 (16.7%)	3 (50.0%)	3 (50.0%)	2 (50.0%)	27 (54.0%)
Antiresorptive/antiangiogenic medication history ^c	2 (33.3%)	7 (87.5%)	5 (62.5%)	6 (100.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	26 (52.0%)

MRONJ, medication-related osteonecrosis of the jaw. ^a Identified as an indication for bisphosphonate therapy. ^b Identified as a medication associated with osteonecrosis of the jaw. ^c Reported routinely asking about antiresorptive or antiangiogenic medication use as part of the medical history. Percentages were calculated within each specialty; specialties are listed in the same order as in Table 1.